Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

OncoSolid™ Esophageal Adenocarcinoma Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Esophageal Adenocarcinoma Cancer Organoid Models

Esophageal cancer ranks as the sixth malignant neoplasm that leads to death worldwide, and the incidence rate of this cancer will elevate to 35% in the years to come. Clinical models of cancer are urgently needed to study the mechanism of tumorigenesis and develop potential therapies for treatment.

Organoid is a self-reorganized 3D culture system that recapitulates the structure of tissue and inherits the intrinsic features of tumor cells. Organoids are physiologically related models that are useful for our understanding of health and disease. With innovative stem cell culture techniques and extensive experience in cancer study, Creative Biolabs offers high-efficiency service for Esophageal Cancers organoids development and various applications for tumor study.

Subtypes of Esophageal Organoids

Esophageal organoids can be generated from different stages of the tumorigenesis process, from normal to neoplastic tissue. Different histological subtypes of esophageal are included.

Methods for Esophageal Organoids Production

3D esophageal organoids can be generated from adult stem cells (ASC), tumor epithelium, and induced pluripotent stem cells (iPSCs), with individual advantages and limitations.

Culture Medium

The medium formulation is crucial for the successful culture of cancer organoids and influences the recapitulation of the structure and function of organoids.

• Different medium is used for the cultivation of normal and cancer tissues.
• Varied media components are supplemented for various histological subtypes of cancer.

Well-characterization of Organoid Models

Features and Advantages

1. High Efficiency
   The organoid forms within two weeks from single cell seeding.
2. Re-organized Histology
   Retain the proliferation-differentiation gradient from the outer to the center of the 3D cell culture.
3. Easy Manipulation
   Organoids allow genetic engineering with CRISPR/Cas9, transposon, and virus vectors, to facilitate cancer study.
4. Allow Stromal Cell Co-culture
   Other cell types, such as immune cells, can be incorporated into organoids to improve the similarity of organoid models to tumor microenvironments.

Cancer-targeted CAR-T Development Services

As a world-famous cell therapy provider, Creative Biolabs has a bank of CAR products for various targets of cancers and is devoted to helping clients explore specific biomarkers of tumor cells. If you want to develop CAR-T products for esophageal adenocarcinoma and use them for cancer organoid tests, please refer to our one-stop CAR-T construction service and CAR-T-related products.

Related Research Data

• Using patient-derived cancer organoids to test drug sensitivity in this model system has been reported for ESCC and EAC.
• Hematoxylin-Eosin (H&E) staining and immunohistochemistry staining of proliferation marker (Ki67), tumor suppressor protein (TP53), ESCC oncogene (SOX2), and EAC marker CDX2.

Fig.1 Histological characterization of ESCC and EAC with matched organoid culture. (Karakasheva, et al., 2020)

Fig.2 Drug response of EAC organoids is measured by size alteration. (Karakasheva, et al., 2020)

Creative Biolabs offers well-characterized cancer organoids-based CAR-Tin vitro efficacy test platform for clients with cost-effective prices and timely reports. Please contact us and get more detailed information.

References

1. Flashner, S.; et al. 3D Organoids: An Untapped Platform for Studying Host-Microbiome Interactions in Esophageal Cancers. Microorganisms. 2021, 9: 2182.
2. Karakasheva, T. A.; et al. Generation and Characterization of Patient-Derived Head and Neck, Oral, and Esophageal Cancer Organoids. Current protocols in stem cell biology. 2020, 53(1): e109.